Acquired Hemophilia A Clinical Trial
Official title:
Emicizumab in Patients With Acquired Hemophilia A: Multicenter, Single-arm, Open-label Clinical Trial
This is a phase II multicenter open-label, single-arm prospective study to evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA).
Patients with AHA who are eligible will receive two loading doses of the study drug, emicizumab (6mg/kg on day 1 and 3 mg/kg on day 2) followed by once weekly subcutaneous emicizumab (1.5 mg/kg). Immunosuppression will be given concurrently as per investigator discretion. The primary endpoint (bleed rate) will be assessed after 12 weeks on study drug. If partial remission of the AHA has not been achieved, an additional 12 weeks of study drug may be given. A historical cohort and a study conducted in parallel in Germany (NCT04188639) will serve as control groups for evaluation of secondary endpoints provided the study cohort are comparable. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03700229 -
Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A
|
Phase 2 | |
| Completed |
NCT04580407 -
Study of TAK-672 in Participants With Acquired Hemophilia A
|
Phase 2/Phase 3 | |
| Completed |
NCT01178294 -
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06461533 -
A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A
|
||
| Completed |
NCT02610127 -
Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
|
||
| Completed |
NCT03384277 -
Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab
|
Phase 4 | |
| Completed |
NCT03199794 -
Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice
|
||
| No longer available |
NCT01968655 -
Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
|